Polymorphisms of microRNA Sequences or Binding Sites and Lung Cancer: A Meta-Analysis and Systematic Review

Zhiwei Chen1*, Ling Xu2, Xiangyun Ye1, Shengping Shen1, Ziming Li1, Xiaomin Niu1, Shun Lu1

1 Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, 2 Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Abstract

Objective: Functional single nucleotide polymorphisms (SNPs) of microRNA (miRNA) sequences or binding sites (miRNA-SNPs) are associated with lung cancer risk and survival. The objective of this study was to systematically review genetic association studies about miRNA-SNPs in lung cancer.

Methods: Eligible genetic association studies were retrieved from databases of PubMed, EMBASE, China National Knowledge Infrastructure and SinoMed. Two investigators selected related studies and assessed methodological quality independently. Quantitative data synthesis was conducted for common SNPs of miRNA (miRNA-196a2 rs11614913, miRNA146a rs2910164, miRNA149 rs2292832, miRNA-605 rs2043556 and miRNA499 rs3746444). GRADE profiler was used to grade the quality of evidence for each miRNA-SNP.

Results: 15 eligible studies and 27 miRNA-SNPs were retrieved and 10 miRNA-SNPs were reported with a significant association with susceptibility to or survival of lung cancer. Methodological quality of eligible studies was adequate with an average score of 8.5. miRNA-196a2 rs11614913 polymorphism was associated with increased lung cancer risk (homozygote comparison, OR = 1.299, 95% CI: 1.096–1.540; dominant model, OR = 1.217, 95% CI: 1.041–1.421) and decreased survival. And according to GRADE profiler, quality of evidence was moderate for MYCL1 rs3134615, while quality of the other significant associations was low.

Conclusions: Based on this first systematic review about miRNA-SNPs in lung cancer, quality of evidence was low for most genetic association studies. Polymorphisms of miRNA-196a2 rs11614913 and MYCL1 rs3134615 could be potential biomarkers of lung cancer.

Introduction

Lung cancer is the leading cause of cancer-related death worldwide [1]. It is widely accepted that both genetic susceptibility and environment exposure contribute to lung cancer and a lot of single nucleotide polymorphisms (SNPs) are associated with lung cancer risk [2,3]. Additionally, recent studies suggested that functional SNPs occurring in micorRNA (miRNA) sequences or binding sites of miRNAs, namely the miRNA-SNPs, were associated with susceptibility to lung cancer [4–7], which highlighted a new paradigm for genetic susceptibility.

miRNAs, a kind of endogenous small non-coding RNAs, are about ~22 nucleotides in length and function as negative regulators of post-transcriptional gene expression [8–10]. Mature miRNAs primarily target the 3′ untranslated region (3′UTR) of their target mRNA, leading to mRNA degradation or suppression of translation [8,11]. miRNAs are crucial for regulation of various biological processes, such as gene regulation, tumorigenesis, proliferation, apoptosis, and metabolism [12–14]. It is estimated that at least 30% of protein coding genes are regulated by miRNAs [15] and on the other hand, a single miRNA can also bind to 3′UTR of many mRNA [16]. SNPs occurring in miRNA sequences can affect processing and binding ability of mature miRNAs. Functional SNPs of miRNA-146a [17], miRNA-499 [18], and miRNA-196a2 [19] have been found associated with cancer susceptibility, including lung cancer. Several studies [4–6] have investigated the correlation between rs11614913 miRNA-196a2 polymorphism and lung cancer risk; however, the results are inclusive.

In addition to polymorphisms of miRNAs, polymorphisms in the binding sites of miRNAs can also contribute to susceptibility of lung cancer. Chin and colleagues [20] identified a novel SNP in the 3′UTR of KRAS gene which altered the binding affinity of miRNA let-7. They also found that this SNP (LCS6) was
associated with lung cancer risk in low-dose smokers. Furthermore, functional miRNA-SNPs may be potential biomarkers to predict clinical outcome of lung cancer.

The current review is the first systematic assessment about SNPs of miRNA sequences and binding sites in lung cancer. In this study, the primary objective was to evaluate the association strength of common miRNA-SNPs with susceptibility to lung cancer. And the secondary objective was systematically reviewing current studies about miRNA-SNPs and risk or clinical outcome of lung cancer and assessing the level of evidence using GRADE profiler.

Methods

Searching Strategy
Eligible studies were extracted by searching electronic databases. A comprehensive search of major databases was conducted, i.e. PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and SinoMed (CBM) were searched. The following key words and medical subheadings were used, “MicroRNAs”, “lung neoplasms”, and “single nucleotide polymorphism”. Alternative spellings were also considered. The last search was performed on December 3, 2012, and there was no limit of languages.

Inclusion and Exclusion Criteria
Eligible studies were selected by two reviewers (Chen and Xu) independently according to following inclusion criteria: 1) investigating miRNA-SNPs and lung cancer risk or clinical outcome; 2) published full-text articles. After the primary screening of titles and abstracts, full-text articles were retrieved and further reviewed for eligibility. The two reviewer reached consensus on each study.

Data Extraction
Two reviewers (Chen and Xu) extracted data from eligible studies in duplicate with a standard data-collection form, and reached consensus on each item. The following data was extracted: name of first author, year of publication, country, ethnicity, number of participants, comparison model, and odds ratios (OR) or hazard ratios (HR) with 95% confidence intervals (CI). For the studies investigating SNPs of miRNA sequences and lung cancer risk, detailed genotype was also collected. Ethnicity descents were simply classified as European and Asian. In the study reported by Nelson and colleagues [20,21], no HR or 95% CIs were available, thus the HR and 95% CIs were estimated from Kaplan-Meier curves using the method proposed by Tierney et al [22].

Methodological Quality Assessment
Two methodological quality scales were adopted to assess quality of eligible studies. For studies about miRNA-SNPs and lung cancer risk, a quality scale (“Table S2: Methodological quality assessment scale for risk”) reported by previous meta-analysis [19] was used. For studies concerning survival of lung cancer and miRNA-SNPs, another quality scale (modified from previous study [23], “Table S3: Methodological quality assessment scale for survival”) was applied. Quality scores of both scales range from 0 to 10, and a high score indicates good quality. Methodological quality of eligible studies was assessed by two investigators independently (Shen and Ye).

GRADE Quality Assessment
GRADE profiler (version 3.6) was adopted to grade quality of evidence for each association. Factors those would upgrade (large effect, plausible confounding, and dose response) and downgrade (risk of bias, inconsistency, indirectness, imprecision, and publication bias) quality of evidence was evaluated. Two investigators (Shen and Ye) assessed quality independently and solved disagreement by discussion.

Statistical Analysis
ORs and 95% CIs were calculated to estimate the association strength of common miRNA-SNPs with lung cancer risk. For lung cancer risk, data synthesis was performed for 5 common SNPs of miRNA [miRNA-196a2 rs11614913, miRNA146a rs2910164, miRNA149 rs2292832, miRNA-605 rs2043556 and miRNA499 rs3746444] but quantitative synthesis was not performed for prognosis with limited data. A number of 4 comparison models were conducted for each SNP, namely homozygote comparison (M1: AA vs. aa), heterozygote comparison (M2: Aa vs. aa), dominant model (M3: AA/Aa vs. aa), and recessive model (M4: AA vs. Aa/aa) (A: variant allele, a: wild allele). Random-effects model (DerSimonian-Laird method) was adopted in each comparison to minimize bias, concerning the limited number of studies. A 95% CI without 1 for OR indicated a significant association with lung cancer risk. Heterogeneity between studies was tested by chi-square based Q test and a P<0.1 indicated significant heterogeneity [24]. Given limited number of studies included in data synthesis, subgroup analysis and sensitivity analysis was not performed. Publication bias was tested by Begg’s test and the Egger’s test and a P value less than 0.05 was considered significant [25].

All P values were two-side. All statistical analyses were calculated with STATA software (version 10.0; StataCorp, College Station, Texas USA).

Results

Selection of Eligible Studies
A total of 135 records were retrieved from databases. After primary screening of titles and abstracts, 17 full-text articles were further reviewed for eligibility. Two articles were excluded for the reason of being abstract [26] and not about miRNA-SNPs [27]. Thus, 15 eligible studies [4–7,20,21,28–36] were retrieved and reviewed and 4 of them [4–7] were included in quantitative synthesis (shown in Figure 1).

Characteristics of Eligible Studies
Table 1 shows characteristics of eligible studies. As shown, 12 of 15 studies were conducted in Asian population and only 3 studies [20,21,29] were performed in European population, which may lead to a discrepancy of ethnicity. Sample sizes of included studies were adequate except for one study reported by Ding et al [30]. All studies were of high methodological quality with an average quality score of 8.5.

Association Strength of miRNA-SNPs and Lung Cancer
A total of 27 miRNA-SNPs were reported in current studies and 10 of them had a significant association with lung cancer risk or survival.

Five common SNPs occurred in miRNA sequences were included in quantitative synthesis, and detail results were shown in Table 2. miRNA-196a2 rs11614913 polymorphism has been demonstrated with increased risk of many cancers, but only 3 studies [4–6] investigated rs11614913 polymorphism and lung cancer risk. By pooling eligible data, we found that the variant C allele increased susceptibility to lung cancer in homozygote comparison (OR = 1.299, 95% CI: 1.096–1.540).
ity = 0.895) and dominant model (OR = 1.217, 95% CI: 1.041–1.421, \( P_{\text{heterogeneity}} = 0.281, P_{\text{Begg}} = 0.296, P_{\text{Egger}} = 0.094 \); Figure 2). However, according to GRADE profiler, the quality of this association was low. No significant association with lung cancer risk was detected for miRNA-149 rs2292832 (dominant model, OR = 1.068, 95% CI: 0.913–1.248, \( P_{\text{heterogeneity}} = 0.975 \), miRNA-146a rs2910164 (dominant model, OR = 1.052, 95% CI: 0.878–1.259), miRNA-499 rs3746444 (dominant model, OR = 0.956, 95% CI: 0.788–1.161), or miRNA-605 rs2043556 (dominant model, OR = 0.840, 95% CI: 0.587–1.203). No evidence of publication bias was detected.

Hu and colleagues [31] investigated the correlation between common SNPs of miRNAs (miRNA-196a2 rs11614913, miRNA-149 rs2292832, miRNA-146a rs2910164, and miRNA-499 rs3746444) and long-term survival of non-small cell lung cancer (NSCLC). They found rs2910164 and rs11614913 were associated with survival and the quality of this association was low according to GRADE profiler (Table 3). But the predictive role of miRNA-196a2 rs11614913 polymorphism differed among NSCLC and small cell lung cancer (SCLC). Zhan and colleagues [28] evaluated the predictive value of rs11614913 polymorphism in SCLC. Zhan [28] did not observe a significant association of rs11614913 polymorphism with response to chemotherapy in SCLC (OR = 0.88, 95% CI: 0.50–1.55); however, rs11614913 polymorphism could predict overall toxicity (OR = 1.73, 95% CI: 1.10–2.71).

Other SNPs of miRNAs were also investigated. Hu et al [32] identified a novel SNPs of miRNA (miR-30c-1 rs928508) in Chinese population, which was associated with survival in NSCLC. Yoon et al [35] explored the prognostic impact of several miRNA polymorphisms in resected NSCLC, and only miR-146a rs2910164 was of predictive value. These two studies were carried out in Asia population and the quality of evidence was low.

Several SNPs of miRNA binding sites were studied and significant association with susceptibility and survival was identified. A total of 6 SNPs in the miRNA binding sites were found associated with lung cancer risk or survival so far (Table 3) but only the association of rs3134615 (3'UTR of MYCL1; OR = 2.08; 95% CI: 1.39–3.12) had a moderate quality [33] (Table 3). Notably, genes in which the polymorphisms of binding sites occurred are oncogenes or involved in DNA repair pathways. For example, REV3L is responsible for DNA repairing [36] and MYCL1 is a member of MYC oncogenes family [33]. Additionally, these polymorphisms could affect gene functions and protein...
Table 1. Characteristics of eligible studies.

| Author | SNP                                                                 | Year | Country  | Ethnicity | Participants | Quality Score |
|--------|----------------------------------------------------------------------|------|----------|------------|--------------|---------------|
| Zhan X | miRNA-196a2 rs11614913                                               | 2012 | China    | Asian      | 442          | 10            |
| Ding C | rs16917496, 3’UTR of SET8                                             | 2012 | China    | Asian      | 44           | 6             |
| Yoon KA| miRNA-219-1 rs213210, miRNA-27a rs895819, miRNA-492 rs2289030, miRNA-146a rs2910164, miRNA-423 rs6505162, miRNA-26a-1 rs7372209 | 2012 | Korea    | Asian      | 388          | 8.5           |
| Zhang S| rs465646, 3’UTR of REV3L                                              | 2012 | China    | Asian      | 2136         | 10            |
| Yang L | rs2735383, 3’UTR of NBS1                                              | 2011 | China    | Asian      | 3328         | 9             |
| Campayo M| rs36603 ’UTR of KRT81                                              | 2011 | Spain    | European  | 175          | 8.5           |
| Xiong F| rs3134615, 3’UTR of MYCL1                                             | 2011 | China    | Asian      | 1424         | 8.5           |
| Hu Z   | let-7a-2 rs629367, miRNA-1–2 rs9989532, miRNA-29c rs2724377, miRNA-30c-1 rs928508, miRNA-31rs13283671, miRNA-33rs9620000, miRNA-125brs2241490, miRNA-145 rs353291, miRNA-193brs30236, miRNA-302dar miRNA-367 rs13136737, and miRNA-378 rs1076064 | 2011 | China    | Asian      | 923          | 9.5           |
| Zhang MW| miRNA-605 rs2043556, miRNA-149 rs2292832                               | 2011 | China    | Asian      | 487          | 8.5           |
| Hong YS| miRNA-196a2 rs11614913                                               | 2011 | Korea    | Asian      | 834          | 7             |
| Kim MJ | miRNA-196a2 rs11614913                                               | 2010 | Korea    | Asian      | 1294         | 8             |
| Nelson HH| 3’UTR of KRAS(LCS6)                                             | 2009 | USA      | European  | 218          | 7             |
| Tian T | miRNA-146a rs2910164, miRNA-149 rs2292832, miRNA-196a2 rs11614913, miRNA-499 rs3746444 | 2009 | China    | Asian      | 2093         | 9.5           |
| Chin LJ| 3’UTR of KRAS(LCS6)                                                | 2008 | USA      | European  | 4245         | 9             |
| Hu Z   | miRNA-146a rs2910164, miRNA-149 rs2292832, miRNA-196a2 rs11614913, miRNA-499 rs3746444 | 2008 | China    | Asian      | 931          | 8.5           |

Figure 2. Forrest plot of miRNA-196a2 rs11614913 (dominant model). Estimated by random-effect model (CC+CT vs. TT).

doi:10.1371/journal.pone.0061008.g002
### Table 2. Meta-analysis results of common SNPs of miRNAs.

| miRNA     | M1                  | M2                  | M3                  | M4                  | GRADE  |
|-----------|---------------------|---------------------|---------------------|---------------------|---------|
| miRNA-146a rs2910164 | 1.125(0.873,1.450) | 1.027(0.849,1.243) | 1.052(0.878,1.259) | 1.107(0.881,1.391) | very low |
| miRNA-149 rs2292832  | 1.159(0.891,1.508) | 1.047(0.889,1.234) | 1.068(0.913,1.248) | 1.131(0.881,1.452) | very low |
| miRNA-196a rs11614913 | 1.299(1.096,1.540)* | 1.204(0.956,1.516) | 1.217(1.041,1.421)* | 1.171(0.996,1.378) | low     |
| miRNA-499 rs3746444  | 0.892(0.508,1.568) | 0.963(0.788,1.177) | 0.956(0.788,1.161) | 0.901(0.514,1.579) | very low |
| miRNA-605 rs2043556  | 0.708(0.337,1.484) | 0.864(0.595,1.256) | 0.840(0.587,1.203) | 0.754(0.366,1.553) | very low |

Results are shown as OR 95% CI; M1: homozygote comparison; M2 heterozygote comparison; M3: dominant model; M4: recessive model; *for significant difference.
doi:10.1371/journal.pone.0061008.t002

### Table 3. miRNA-SNPs and lung cancer.

| Author  | SNP        | Correlation                   | Comparison Model and P value | GRADE quality | Reason          |
|---------|------------|-------------------------------|------------------------------|---------------|-----------------|
| Zhan X  | miRNA-196a2 rs11614913 | response to chemotherapy       | CC vs. CT/TT; OR, 0.88, 95% CI:0.50–1.55 | very low     | imprecision     |
|         |            |                               | overall toxicity             |               |                 |
| Yoon KA | miRNA-219-1 rs213210  | recurrence-free survival       | AG/GG vs. AA; HR,1.17; 95% CI:0.67–2.03 | very low     | imprecision     |
|         | miRNA-27a rs95819     |                               | CT/CC vs. TT; HR,0.98; 95% CI:0.61–1.60 | very low     | imprecision     |
|         | miRNA-492 rs2289030   |                               | CG/CC vs. GG; HR,1.04; 95% CI:0.65–1.69 | very low     | imprecision     |
|         | miRNA-146a rs2910164  |                               | CC/GG vs. CC; HR,0.52; 95% CI:0.32–0.85* | low          |                 |
|         | miRNA-423 rs6505162   |                               | AC/AA vs. CC; HR,1.09; 95% CI:0.67–1.77 | very low     | imprecision     |
| Hu Z    | miRNA-30c-1 rs928508 | survival                      | AG/GG vs. AA; HR,0.73; 95% CI:0.61–0.89* | low          |                 |
| let-7a-2 rs29367 |                       |                               | AG/CC vs. AA; HR,0.91; 95% CI:0.66–1.26 | very low     | imprecision     |
| miRNA-1-2 rs9989532 |                       |                               | AG/GG vs. AA; HR,0.78; 95% CI:0.49–1.24 | very low     | imprecision     |
| miRNA-29c rs2724377 |                       |                               | GG vs. AA/AG; HR,1.35; 95% CI:0.49–3.68 | very low     | imprecision     |
| miRNA-31 rs13283671 |                       |                               | GG vs. AA/AG; HR,1.82; 95% CI:1.05–3.18** | very low     |                 |
| miRNA-33 rs9620000 |                       |                               | AG vs. AA; HR,1.23; 95% CI:0.83–1.82 | very low     | imprecision     |
| miRNA-125b rs2241490 |                       |                               | AA vs. GG/GA; HR,1.20; 95% CI:0.72–2.01 | very low     | imprecision     |
| miRNA-145 rs353291  |                       |                               | AG/GG vs. AA; HR,1.47; 95% CI:1.04–2.07** | low          |                 |
| miRNA-193b rs30236  |                       |                               | AA vs. GG/GA; HR,1.02; 95% CI:0.63–1.68 | very low     | imprecision     |
| miRNA-378 rs1076064 |                       |                               | AG/GG vs. AA; HR,1.10; 95% CI:0.77–1.58 | very low     | imprecision     |
| miRNA-302d rs13136737 |                   |                               | CA/AA vs. CC; HR,0.92; 95% CI:0.67–1.25 | very low     | imprecision     |
| Hu Z    | miRNA-146a rs2910164 | survival                      | GG vs. CC; HR,1.28; 95% CI:0.89–1.82 | very low     | imprecision     |
| miRNA-149 rs2292832 |                       |                               | TT vs. GG/GT; HR,1.29; 95% CI:1.01–1.65* | low          |                 |
| miRNA-196a2 rs11614913 |                   |                               | CC vs. TT/CT; HR,1.76; 95% CI:1.34–2.33* | low          |                 |
| miRNA-499 rs3746444 |                       |                               | GG vs. AA; HR,1.24; 95% CI:0.55–2.83 | very low     | imprecision     |
| Ding C  | rs16917496, 3' UTR of SE7 | 2 year survival               | CT/CC vs. TT; HR,0.59; 95% CI:0.33–1.06* | very low     | imprecision     |
| Zhang S | rs465646, 3' UTR of REV3L susceptible |                       | TC/CC vs. TT; OR,0.71; 95% CI:0.50–0.85* | low          |                 |
| Yang L  | rs2735383, 3'UTR NFBS1 susceptibility |                       | CC vs. GG/GG; OR,1.40; 95% CI:1.18–1.66* | low          |                 |
| Campayo M | rs36603' UTR of KRT81 time to recurrence |                       | CG/GG vs. CC; HR,0.51; 95% CI:0.35–0.74* | low          |                 |
| Xiong F | rs3134615, 3' UTR of MYCL1 susceptibility |                       | GT/TT vs. GG; OR,2.08; 95% CI:1.39–3.12* | moderate     | large effect    |
| Nelson HH | 3' UTR of KRAS(LC56) 5 year survival |                       | TG/GG vs. TT; HR,0.99; 95% CI:0.56–1.74* | low          |                 |
| Chin LJn | 3' UTR of KRAS(LC56) susceptibility |                       | TG/GG vs. TT; OR,1.36; 95% CI:1.07–1.73* | low          |                 |

*significant association;
a: different results between screening set and validation set;
b: HR and 95% CI estimated form Kaplan-Meier curve;
c: data from the validation set; d: data from low-dose smokers of Boston case-control study;
doi:10.1371/journal.pone.0061008.t003
expression, which was consistent with predictive role of these miRNA-SNPs.

Chiu et al [20] identified a polymorphism in the 3’UTR of KRAS (LCS6) and the LCS6 polymorphism increased lung cancer risk in low-dose smokers (GRADE quality of evidence, low) but this association was not significant in overall population (GRADE quality of evidence, very low). Therefore, Nelson and colleagues [21] investigated LCS6 polymorphism and survival of lung cancer and failed to find any significant association (HR = 0.99, 95% CI: 0.56–1.74). Intriguingly, these two studies about LCS6 polymorphism were both carried out in Europe population, and the LCS6 polymorphism has not been validated in other ethnicities.

Each of the 6 SNPs in miRNA binding sites was reported in one single study, and due to imprecision, these studies could not provide evidence of high quality.

Discussion

In this first extensive systematic review about miRNA-SNPs in lung cancer, we identified 15 genetic association studies on this topic and evaluated the quality of evidence of 27 miRNA-SNPs. Methodological quality of eligible studies was adequate and GRADE profiler suggested that the association level of most miRNA-SNPs was low, except for rs3134615 polymorphism in the 3’UTR of MYCL1 [33] (moderate).

Numerous studies have investigated the common SNPs of miRNA and risks of different kinds of cancer. In this study, we found polymorphism of miRNA-196a2 increased lung cancer risk in homozygote comparison (OR = 1.299, 95% CI: 1.096–1.540) and dominant model (OR = 1.217, 95% CI: 1.041–1.421). And the polymorphisms of miRNA-146a, miRNA-149, and miRNA-499 did not show any significant association, though altered risk was observed in other cancers. However, in the study by Hu et al [31], polymorphisms of miRNA-149 and miRNA-196a2 were significantly correlated with long-term survival of NSCLC. Additionally, Zhan and colleagues [28] showed that miRNA-196a2 rs11614913 could predict overall toxicity of chemotherapy in NSCLC. These results suggest that miRNA-196a2 rs11614913 polymorphisms may be a potential biomarker for risk of lung cancer and clinical outcome of NSCLC.

Six SNPs in the binding sites of miRNA were retrieved from eligible studies and all of them were associated with susceptibility to or survival of lung cancer. But only rs3134615 (3’UTR of MYCL1) showed moderate quality [33], which highlights the role of rs3134615 as a potential biomarker in SCLC. As few studies investigated genetic variation in SCLC, the polymorphism of MYCL1 should further validated in different ethnicities with a large sample size. Ding and colleagues indentified a SNP at rs16917496, the 3’UTR of SET8 [30], and found it associated with survival of SCLC. Intriguingly, SET8, a methyltransferase, modulates p53 expression [37]. Additionally, the prognostic value of KRT81 rs3660 polymorphism was more marked in squamous cell cancer [29]. Although the association level of KRT81 rs3660 and SET8 rs16917496 was low according to GRADE profiler, further studies are warrant.

These SNPs of miRNA binding sites were located in oncogenes or critical genes involved in DNA repairing pathways. These genes are critical for carcinogenesis and integrity of genome. Based on features of these host genes, we might infer that other SNPs in the 3’UTR of oncoenes or DNA repair genes would be possibly of predictive value for cancer risk or survival.

Based on our systematic review, some weakness of current studies was identified. At first the association level identified by current studies was low because of imprecision according to GRADE profiler. Additionally, most SNPs were identified by one single study and no further validation was available. Secondly, most studies were carried out in Asian population and only 3 studies [20,21,29] and 2 SNPs were performed in European polulation. Furthermore, of 7 studies [20,21,29,30,33,34,36] about SNPs of miRNA binding sites, only one study [33] reported insignificant correlation with lung cancer survival, which indicated the existence of publication bias.

In conclusion, we identified 10 SNPs of miRNA sequences or binding sites that were associated with lung cancer risk or survival. However, the quality of evidence was low according to GRADE profiler. Weakness of current studies was stressed and translational potential of miRNA-196a2 rs11614913 and MYCL1-rs3134615 was also discussed.

Supporting Information

Table S1 PRISMA checklist.

Table S2 Methodological quality assessment scale for risk.

Table S3 Methodological quality assessment scale for survival.

Author Contributions

Conceived and designed the experiments: ZC LX XY SS ZL XN SL. Wrote the paper: ZC LX XY SS ZL XN SL. Performed the experiments: ZC LX XY SS ZL. Analyzed the data: ZC LX XY SS ZL SL. Contributed reagents/materials/analysis tools: ZC LX XY SS ZL XN SL. Drafted the manuscript: ZC LX XY SS ZL XN SL. Conceived and designed the experiments: ZC LX XY SS ZL XN SL. Wrote the paper: ZC LX XY SS ZL XN SL.

References

1. Jemal A, Siegel R, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
2. Kiyohara C, Horiiuchi T, Takayama K, Nakaniishi Y (2012) Genetic polymorphisms involved in carcinogenesis metabolism and DNA repair and lung cancer risk in a Japanese population. J Thorac Oncol 7: 954–962.
3. Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, Pascual T, Marron MG, et al. (2007) Polymorphisms in XPC, XPD, XPG, XRC1, and XRC5 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer 7: 162.
4. Hong YS, Kang HJ, Kwak JY, Park BL, You CH, et al. (2011) Association of miR-605 and miR-149 genetic polymorphisms with related risk factors of lung cancer susceptibility. Zhejiang Da Xue Xue Bao Yi Xue Ban 40: 265–271.
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
6. Mendell JT (2005) MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 4: 1179–1184.
7. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 315–324.
8. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
9. Ambros V, Forstmann K (2008) Roles of microRNAs beyond development-metabolism and neural plasticity. Biochim Biophys Acta 1779: 692–696.
10. Gregory RI, Shiekhattar R (2005) MicroRNA biogenesis and cancer. Cancer Res 65: 3505–3512.
11. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, et al. (2008) Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451: 1125–1129.
15. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.

16. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495–500.

17. Wang Z, Cao Y, Jiang C, Yang G, Wu J, et al. (2012) Lack of association of two common polymorphisms rs2910164 and rs1614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One 7: e40039.

18. Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, et al. (2012) Hsa-miR-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoS One 7: e50887.

19. Guo J, Jin M, Zhang M, Chen K (2012) A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One 7: e30585.

20. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, et al. (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3’ untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535–8540.

21. Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, et al. (2010) KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69: 51–53.

22. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.

23. Wu J, Liu J, Zhou Y, Ying J, Zou H, et al. (2012) Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clinic Cancer Res 18: 3972–3983.

24. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820–826.

25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

26. Hu Z, Zhao Y, Tian T, Liang J, Jin G, et al. (2009) Association between microRNA polymorphisms, expressions, lung cancer development and prognosis. BioMedicine and Pharmacotherapy 63: 323.

27. Vinci S, Gelmini S, Pratesi N, Conti S, Malenatichi F, et al. (2011) Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chim Lab Med 49: 2073–2080.

28. Zhang X, Wu W, Han B, Gao G, Qiao R, et al. (2012) HmarmiR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal 26: 441–446.

29. Campayo M, Navarro A, Vinas N, Tejero R, Munoz C, et al. (2011) A dual role for KRT81: a miR-502 associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One 6: e25296.

30. Ding C, Li R, Feng J, Li S, Gao Z (2012) A polymorphism at the miR-502 binding site in the 3’ untranslated region of the NET8 gene is associated with the outcome of small-cell lung cancer. Exp Ther Med 3: 689–692.

31. Hu Z, Chen J, Tian T, Zhou X, Gu H, et al. (2008) Genetic variants of microRNA sequences and non-small-cell lung cancer survival. J Clin Invest 118: 2600–2608.

32. Hu Z, Shu Y, Chen Y, Chen J, Dong J, et al. (2011) Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Ann J Respir Crit Care Med 183: 641–648.

33. Xiong F, Wu C, Chang J, Yu D, Xu B, et al. (2011) Genetic variation in an miR-302 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 71: 5173–5181.

34. Yang L, Li Y, Cheng M, Huang D, Zheng J, et al. (2012) A functional polymorphism at microRNA-629-binding site in the 3’-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis 33: 338–347.

35. Yoon KA, Yoon H, Park S, Jang HJ, Zo JJ, et al. (2012) The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 144: 794–807.

36. Zhang S, Chen H, Zhao X, Cao J, Tong J, et al. (2013) REV3L 3’UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene 32: 242–250.

37. Shi X, Kachirskaja I, Yamaguchi H, West LE, Wen H, et al. (2007) Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 27: 636–646.